Dr. Diyuan Li
Diyuan Li obtained his BSc degree in pharmacy at China Pharmaceutical University (2014) and MSc in Chemistry from The University of Manchester (2016). He has two industrial experiences: synthesis of Tofacitinib, a new drug of Pfizer at Jinlixin Medical Co.Ltd. (2014) and drug intermediate synthesis and scale up at Peptech corp., China (2017). He holds a PhD degree in organic chemistry from University College London (Dr Wilden’s group), where he acquired a great deal of experience with radical chemistry and electrosynthesis. From July 2021 to May 2022, he was a postdoctoral research fellow at University of Nottingham, where he focused on visible light induced peptide and protein modification.